Development of a Sovereign End-to-End Supply Chain for Alpha-Emitter Production to Support Global Targeted Alpha Therapy in Australia and the Pacific.
Targeted Alpha Therapy (TAT) using actinium-225 and its short-lived daughter isotopes is emerging as one of the most powerful modalities for treating metastatic and refractory cancers. However, worldwide supply of actinium-225 remains critically limited (<5 Ci annually), constraining clinical access...
| Published in: | Journal of Medical Imaging & Radiation Sciences Vol. 57; no. 2 |
|---|---|
| Main Author: | |
| Format: | research Journal Article |
| Published: |
Elsevier B.V.
Mar2026 Supplement
|
| Online Access: | View this record in EBSCOhost |